Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.49 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | NOS3 | P29474 | 2/20 | 0.49 |
| ▸ | ARG1 | P05089 | 1/20 | 0.46 |
| ▸ | ARG2 | P78540 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | BHMT | Q93088 | 2/20 | 0.37 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210387 | 1.00 | NOS2 (0.49) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL3928876 | 1.00 | NOS2 (0.49) | NOS2NOS1NOS3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL4223447 | 0.98 | NOS2 (0.47) | NOS2NOS1NOS3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL29401714 | 0.98 | NOS2 (0.47) | NOS2NOS1NOS3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL4223453 | 0.98 | NOS2 (0.47) | NOS2NOS1NOS3ARG1ARG2 | |
| Trifluoroacetic Acid SCHEMBL9659589 | 0.90 | NOS2 (0.42) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL8894370 | 0.85 | NOS2 (0.38) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL1679688 | 0.84 | ARG1 (0.48) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL1679691 | 0.84 | ARG1 (0.48) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL11717051 | 0.84 | NOS2 (0.45) | NOS2NOS1NOS3ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1605 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOC DES PRODUITS NESTLE S A (CH) | 2026-05-21 | — | — | US | claimed |
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-02-03 | — | — | US | claimed |
| US-20250281438-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-09-11 | — | — | US | claimed |
| CN-116546981-A | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof and at least one thymol and/or carvacrol | 雀巢产品有限公司 | 2023-08-04 | — | — | CN | claimed |
| EP-4000627-A1 | TREATMENT OF ABDOMINAL AORTIC ANEURYSM AFTER ITS CLINICAL MANIFESTATION | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz (ES) | 2022-05-25 | — | — | EP | claimed |
| EP-1874948-B1 | Process for the production of y-glutamylcysteine | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2013-03-20 | — | — | EP | claimed |
| US-8236533-B2 | Process for the production of γ-glutamylcysteine | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2012-08-07 | — | — | US | claimed |
| EP-1163262-B1 | PHENYLALANINE DERIVATIVES | US GOV HEALTH & HUMAN SERV (US) | 2011-05-11 | — | — | EP | claimed |
| US-20110020311-A1 | Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy | BOUCHER JAMES LAYNE | 2011-01-27 | — | — | US | claimed |
| US-20090136993-A1 | Process for the Production of Gamma-Glutamylcysteine | NEWSOUTH INNOVATIONS PTY LIMITED | 2009-05-28 | — | — | US | claimed |
| EP-1383792-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2004003005-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-01-08 | — | — | WO | claimed |
| WO-2002016407-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-02-28 | — | — | WO | claimed |
| EP-1163262-A1 | PHENYLALANINE DERIVATIVES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000056760-A1 | PHENYLALANINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | claimed |
| EP-0792170-A4 | RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS | NEORX CORP (US) | 2000-03-15 | — | — | EP | claimed |
| EP-0792170-A1 | RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS | NEORX CORPORATION (US) | 1997-09-03 | — | — | EP | claimed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | claimed |
| WO-1995002418-A1 | RADIONUCLIDE METAL CHELATES FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS | NEORX CORPORATION (US) | 1995-01-26 | — | — | WO | claimed |
| US-4960881-A | REACTING AMINO ACID WITH ALPHA-CHLORINATED CARBONATE IN SOLVENT IN PRESENCE OF ACID SCAVENGER | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1990-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020311-A1 | Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy | ADA, ADORA2B, AHCY | NOS2 2311/4885NOS1 2088/4885NOS3 2132/4885 |
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | LIPC, GGT1, TGM2 | NOS2 960/4885NOS1 678/4885NOS3 1112/4885 |
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | LIPC, GGT1, TGM2 | NOS2 876/4885NOS1 640/4885NOS3 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.